Apmonia Tx announces a €2.7M financing to develop its clinical candidate and strengthen its discovery platform
These non-dilutive funds, granted as part of France 2030 plan, will enable Apmonia Therapeutics to initiate clinical trials with its TAX2 drug candidate in various